Impact of Powdered Tart Cherries on Recovery From Repeated Sprints

NCT06122038 | Completed

• 1 other identifier: IRB-23-11
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate changes in force and power production, soreness, inflammation, and oxidative stress after repeated sprinting activity and powdered tart cherry ingestion in trained males and females.

Conditions

Oxidative Stress; Soreness, Muscle; Inflammation; Muscle Damage

Keywords

Tart Cherry; Inflammation; Muscle Soreness; Muscle Damage

Outcome Measures

Primary Outcomes (11)

• Counter movement Jump Height

  Jump height from counter movement jump

  10 days

• Counter movement jump peak propulsive force (N)

  Peak propulsive force (N) from counter movement jump

  10 days

• Counter movement jump relative breaking force (N)

  relative breaking force (N/kg) from counter movement jump

  10 days

• Isokinetic knee extension maximal voluntary contraction.

  Peak isokinetic knee extension force (N) from a isokinetic knee extension exercise using a Biodex System 3

  10 days

• Isometric mid-thigh pull maximal voluntary contraction

  Isometric maximal voluntary contraction peak force will be measured using an isometric mid-thigh pull assessment. Peak force production will be measured in Newtons.

  10 days

• Perceived recovery Visual Analog Scale

  Perceived recovery Visual Analog Scale ranging from 0 (worst) to 100 (best)

  10 days

• Perceived soreness Visual Analog Scale

  Perceived soreness Visual Analog Scale ranging from 0 (worst) to 100 (best)

  10 days

• Pain to Pressure threshold

  Pain to Pressure threshold from algometry (higher = less sore). Minimum values are 0 N, maximum values are 110 N

  10 days

• Changes in Creatine Kinase concentrations

  Changes in Creatine kinase concentrations following damaging exercise

  10 days

• Changes in Creatine Kinase-myocardial band concentrations

  Changes in Creatine kinase-myocardial band concentrations following damaging exercise

  10 days

• Sprint time

  Fastest and average sprint time during 15 30-meter sprint recorded using digitally timed timing gates

  Baseline

Secondary Outcomes (10)

• Peak power

  10 days

• Changes in Protein carbonyls concentration

  10 days

• Changes in 8-isoprostane concentration

  10 days

• Changes in testosterone-cortisol ratio

  10 days

• Changes in TNF-alpha concentration

  10 days

Other Outcomes (3)

• Resting Heart Rate

  10 days

• Resting Blood pressure

  10 days

• Reported Adverse Events

  10 days

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Rice Flour. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.

Dietary Supplement: Placebo

Tart Cherry Extract Powder

EXPERIMENTAL

Tart Cherry Extract Powder (ADSO Naturals). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.

Dietary Supplement: Tart Cherry Extract Powder

Interventions

Tart Cherry Extract Powder DIETARY_SUPPLEMENT

Tart Cherry Extract Powder (ADSO Naturals). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.

Tart Cherry Extract Powder

Placebo DIETARY_SUPPLEMENT

Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.

Placebo

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male and female (n=40) participants between the ages of 18 - 35 years of age will finish the study protocol. An even distribution of males (n=20) and females (n=20) is planned.
• Participating in some form of exercise at least four days per week with at least two days consisting of some form of high-intensity exercise for the past six months.
• Examples include regular gym attendance to complete resistance training, interval exercise, or participation in some form of organized physical activity involving high-speed running or other forms of high-intensity exercise.
• Have a body mass index (BMI) range of 18.0 - 30.0 kg/m2. Males with a body mass index greater than 30.0 kg/m2, but a body fat percentage less than 27.5% fat will be accepted into the study. Females with a body mass index greater than 30.0 kg/m2, but a body fat percentage less than 32.5% fat will be accepted into the study.

You may not qualify if:

• Participant has a positive medical history of heart disease/cardiovascular disease, uncontrolled hypertension (140/90 or greater mmHg), kidney disease (dialysis or renal failure), hepatic impairment or disease, or Type I or Type II diabetes.
• Participant has a positive medical history of unstable thyroid disease, previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorder (i.e., HIV/AIDS), a history of cancer (except localized skin cancer without metastases or in situ cervical cancer within five years prior to screening visit.
• Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g. dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)
• Positive medical history for any neurological condition or neurological disease
• Currently smoke or have quit within the past six months
• Current daily use of aspirin, NSAIDS, naproxen sodium, COX-2 inhibitors, or any other over-the-counter or prescribed medication indicated for pain relief.
• Intake of any dietary supplement known or purported to impact muscle repair and recovery such as antioxidants, curcumin, turmeric, branched-chain amino acids, vitamin D, tart cherry, pomegranate, fish oils, or creatine monohydrate.
• Individuals who indicate they are actively involved in any form of a dietary program in the past 30 days to lose weight
• Participants who are lactating, pregnant or planning to become pregnant
• Have a known sensitivity or allergy to any of the study products
• Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data
• History of alcohol or substance abuse in the 12 months prior to screening
• Receipt or use of an investigational product in another research study within 28 days prior to baseline testing

Sponsors & Collaborators

• Lindenwood University: lead

Study Sites (1)

Exercise and Performance Nutrition Laboratory

Saint Charles, Missouri, 63301, United States

Location

MeSH Terms

Conditions

Inflammation; Myalgia

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Musculoskeletal Pain; Pain; Neurologic Manifestations; Signs and Symptoms

Study Officials

• Chad M Kerksick, PhD

  Lindenwood University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: In a double-blind, placebo-controlled fashion, participants will be randomly assigned to one of two supplementation groups. One group will be assigned to ingest rice flour which will serve as a placebo group. The other group will be assigned to ingest 500 mg/day of Tart Cherry Extract Powder (ADSO Naturals). All study materials will be prepared into gelatin capsules of identical size, color, shape, and transparency.
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This study will utilize a randomized, double-blind, placebo group study design

Study Record Dates

• First Submitted: May 15, 2023
• First Posted: November 8, 2023
• Study Start: April 25, 2023
• Primary Completion: December 20, 2023
• Study Completion: December 20, 2023
• Last Updated: January 13, 2026

Record last verified: 2024-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)